Therapeutic area intelligence for Biologic Therapy with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Companies: 1

Companies

Amgen →

Assets

PAVBLU →

Recent signals(1)

RegulatoryJuly 8, 2026

FDA Accepts Application for PAVBLU (Aflibercept-AYYH) from Amgen

The FDA has accepted the application for PAVBLU, a biologic therapy containing Aflibercept-AYYH.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.